NASDAQ:DNTH • US2528281080
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for DIANTHUS THERAPEUTICS INC (DNTH).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-19 | Wells Fargo | Initiate | Overweight |
| 2026-03-12 | Wedbush | Maintains | Outperform -> Outperform |
| 2026-03-10 | Clear Street | Maintains | Buy -> Buy |
| 2026-03-10 | Wedbush | Maintains | Outperform -> Outperform |
| 2026-03-10 | Raymond James | Upgrade | Outperform -> Strong Buy |
| 2026-03-10 | Baird | Maintains | Outperform -> Outperform |
| 2026-03-09 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2026-03-09 | Truist Securities | Maintains | Buy -> Buy |
| 2026-03-09 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-03-04 | Guggenheim | Maintains | Buy -> Buy |
| 2026-02-11 | Wedbush | Maintains | Outperform -> Outperform |
| 2026-02-02 | Jefferies | Maintains | Buy -> Buy |
| 2026-01-08 | Truist Securities | Maintains | Buy -> Buy |
| 2025-12-22 | Wedbush | Reiterate | Outperform -> Outperform |
| 2025-11-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-06 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-10-14 | Truist Securities | Initiate | Buy |
| 2025-09-17 | Clear Street | Initiate | Buy |
| 2025-09-12 | Stifel | Maintains | Buy -> Buy |
| 2025-09-12 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-09-09 | Guggenheim | Maintains | Buy -> Buy |
| 2025-09-09 | Raymond James | Reiterate | Outperform -> Outperform |
| 2025-09-09 | Baird | Maintains | Outperform -> Outperform |
| 2025-09-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-21 | Wedbush | Maintains | Outperform -> Outperform |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 2.826M | 6.235M 120.63% | 2.036M -67.35% | 1.398M -31.34% | 1.822M 30.33% | 17.557M 863.61% | 142.8M 713.35% | 496.6M 247.76% | 783.05M 57.68% | 1.115B 42.39% | 1.414B 26.82% | |
| EBITDA YoY % growth | -48.107M 39.08% | -101.768M -111.55% | -177.822M -74.73% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -48.174M 40.45% | -101.864M -111.45% | -177.933M -74.68% | -228.854M -28.62% | -268.547M -17.34% | -308.67M -14.94% | -198.451M 35.71% | 48.808M 124.59% | 259.89M 432.47% | 477.55M 83.75% | 679.36M 42.26% | |
| Operating Margin | -1,704.67% | -1,633.74% | -8,739.34% | -16,370.14% | -14,739.14% | -1,758.10% | -138.97% | 9.83% | 33.19% | 42.83% | 48.05% | |
| EPS YoY % growth | -12.97 37.16% | -2.60 79.95% | -4.10 -57.69% | -3.83 6.65% | -4.46 -16.66% | -4.73 -5.85% | -5.31 -12.38% | -2.15 59.48% | -1.01 52.84% | 2.53 349.75% | 6.45 154.33% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.08 -32.30% | -1.10 -25.02% | -1.14 -17.62% | -1.25 12.57% | -1.10 -1.54% | -1.11 -0.83% | -1.09 4.79% | -1.41 -13.00% |
| Revenue Q2Q % growth | 369.454K -68.23% | 308.55K 59.87% | 311.824K -21.26% | 357.071K 25.73% | -100.00% | -100.00% | -100.00% | -100.00% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -51.142M -54.15% | -53.176M -52.25% | -55.821M -38.56% | -63.023M 9.37% | -54.807M -7.17% | -55.452M -4.28% | -54.006M 3.25% | -73.757M -17.03% |
All data in USD
21 analysts have analysed DNTH and the average price target is 130.48 USD. This implies a price increase of 52.26% is expected in the next year compared to the current price of 85.695.
DIANTHUS THERAPEUTICS INC (DNTH) will report earnings on 2026-05-11.
The consensus EPS estimate for the next earnings of DIANTHUS THERAPEUTICS INC (DNTH) is -1.08 USD and the consensus revenue estimate is 369.45K USD.
The consensus rating for DIANTHUS THERAPEUTICS INC (DNTH) is 87.619 / 100 . This indicates that analysts generally have a positive outlook on the stock.